✦ LIBER ✦

Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction

✍ Scribed by Geraldine M. Ferron; Richard A. Preston; Robert J. Noveck; Paul Pockros; Philip Mayer; John Getsy; Marybeth Turner; Madelyn Abell; Jeffrey Paul

Book ID: 117321139
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 620 KB
Volume: 23
Category: Article
ISSN: 0149-2918
DOI: 10.1016/s0149-2918(01)80100-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of oxaliplatin in patie

Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction

✍ Martina Baur; Anne Drescher; Margit Gneist; Christian Dittrich; Ulrich Jaehde 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 187 KB

Pharmacokinetics of micafungin in subjec

Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction

✍ Undre, Nasrullah; Pretorius, Benjamin; Stevenson, Paul 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 482 KB

Pharmacokinetics and dosage adjustment i

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

✍ Roger K. Verbeeck 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 315 KB

Pharmacokinetics of sabeluzole and dextr

Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers

✍ G. P. Pageaux; J. Micallef; M. Barugola Nataf; J. C. Levron; B. Lacarelle; J. P. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

Pharmacokinetics of eslicarbazepine acet

Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment

✍ Luis Almeida; J. Hendrick Potgieter; Joana Maia; M. Alida Potgieter; Fernando Mo 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 188 KB

Pharmacokinetics of benzodiazepine antag

Pharmacokinetics of benzodiazepine antagonist Ro 15–1788 in cirrhotic patients with moderate or severe liver dysfunction

✍ Gilles Pomier-Layrargues; J.-François Giguère; Joël Lavoie; Bernard Willems; Rog 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 437 KB

Ro 15-1788, a benzodiazepine antagonist, has been advocated as a new treatment for hepatic encephalopathy. This drug is extensively metabolized by the liver in normal subjects. In the present study, we examined Ro 15-1 788 disposition in eight healthy controls (Group I), eight cirrhotic patients wit